Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519532 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT00519532 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 84 participants.
The verdict
NCT00519532, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.
Interventions
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519532
The ClinicalTrials.gov registry entry for NCT00519532 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rotigotine is the first listed.
NCT00519532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00519532 about?
NCT00519532 is a clinical study titled "Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease". The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will...
What is the current status of trial NCT00519532?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2007-07. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00519532?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00519532?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.